Pamela M. Arway Sells 625 Shares of Davita Inc (NYSE:DVA) Stock

Davita Inc (NYSE:DVA) Director Pamela M. Arway sold 625 shares of the company’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $71.25, for a total value of $44,531.25. Following the completion of the sale, the director now owns 19,239 shares of the company’s stock, valued at $1,370,778.75. The transaction was disclosed in a filing with the SEC, which is available through this link.

Shares of DVA stock opened at $70.20 on Thursday. Davita Inc has a 52-week low of $43.40 and a 52-week high of $90.15. The company has a debt-to-equity ratio of 4.61, a quick ratio of 1.51 and a current ratio of 1.56. The firm has a market capitalization of $8.62 billion, a PE ratio of 13.07, a PEG ratio of 0.56 and a beta of 1.61. The stock has a fifty day simple moving average of $79.01 and a two-hundred day simple moving average of $70.97.

Davita (NYSE:DVA) last issued its quarterly earnings results on Monday, February 10th. The company reported $1.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.66 by $0.20. Davita had a return on equity of 25.18% and a net margin of 7.12%. The business had revenue of $2.90 billion during the quarter, compared to analyst estimates of $2.92 billion. During the same quarter in the prior year, the business posted $0.90 EPS. Davita’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, sell-side analysts forecast that Davita Inc will post 6.06 EPS for the current fiscal year.

Several equities research analysts have recently commented on the company. ValuEngine upgraded Davita from a “sell” rating to a “hold” rating in a research note on Tuesday, March 17th. Goldman Sachs Group upgraded Davita from a “neutral” rating to a “buy” rating in a research note on Friday, January 24th. Zacks Investment Research upgraded Davita from a “hold” rating to a “strong-buy” rating and set a $93.00 price target for the company in a research note on Wednesday, February 12th. Deutsche Bank initiated coverage on Davita in a research note on Friday, January 3rd. They issued a “buy” rating and a $60.00 price target for the company. Finally, SunTrust Banks set a $90.00 price target on Davita in a research note on Tuesday, February 11th. Nine equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Davita has a consensus rating of “Hold” and a consensus target price of $71.43.

Several institutional investors have recently modified their holdings of DVA. Resources Management Corp CT ADV purchased a new position in shares of Davita during the third quarter valued at about $33,000. Duncker Streett & Co. Inc. purchased a new position in shares of Davita during the fourth quarter valued at about $47,000. Neo Ivy Capital Management grew its position in shares of Davita by 61.2% during the third quarter. Neo Ivy Capital Management now owns 1,743 shares of the company’s stock valued at $98,000 after purchasing an additional 662 shares in the last quarter. Vestcor Investment Management Corp purchased a new position in shares of Davita during the fourth quarter valued at about $117,000. Finally, Northwestern Mutual Wealth Management Co. grew its position in shares of Davita by 163.8% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,469 shares of the company’s stock valued at $185,000 after purchasing an additional 1,533 shares in the last quarter. Hedge funds and other institutional investors own 93.59% of the company’s stock.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Story: Call Option Volume

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.